Levofolic

Levoleucovorin Disodium, the active ingredient in Levofolic, is a reduced form of folic acid presented as an intravenous solution for IV use. It is employed to mitigate antifolate toxicity and to support nucleotide synthesis in patients undergoing certain chemotherapy regimens.

GNH USA supplies Levofolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customer support is available to assist with regulatory documentation and import procedures.

Levofolic (levoleucovorin disodium) is used in clinical settings that involve antifolate chemotherapy and folate deficiency. - Methotrexate toxicity: rescues normal cells from methotrexate‑induced folate depletion. - 5‑Fluorouracil‑based chemotherapy: enhances the cytotoxic effect of 5‑FU in solid tumors. - Folate deficiency: supplies a bioavailable form of folate to support DNA and RNA synthesis.

Levofolic may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Flushing: brief redness or warmth of the skin. Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, bronchospasm, or anaphylaxis. - Renal impairment: decreased kidney function in susceptible patients. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Before initiating Levofolic therapy, clinicians should consider several safety measures. - Assess renal function: evaluate baseline creatinine clearance before initiation. - Monitor liver enzymes: check hepatic function during therapy. - Adjust dose in elderly: consider reduced dosing for older patients with comorbidities. - Avoid concurrent high‑dose antifolates: do not combine with other antifolate agents without specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofolic can interact with other medicines; some combinations require avoidance while others need close monitoring. Major Interactions (Avoid): - Methotrexate: concurrent use may reduce methotrexate efficacy; timing must be managed. - High‑dose folic acid supplements: may interfere with intended rescue effect. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): can increase risk of renal toxicity. Moderate Interactions (Monitor Closely): - 5‑Fluorouracil: levoleucovorin enhances cytotoxicity; dose adjustments may be required. - Cytarabine: potential additive myelosuppression. - NSAIDs: may affect renal clearance of the drug.